دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Action on ultra-processed foods needs robust evidence
doi : 10.1016/S2468-1253(24)00405-9
Volume 10, Issue 1, January 2025, Page 1
Vedolizumab prophylaxis against postoperative Crohn's disease recurrence
Oncological safety of laparoscopic surgery for low rectal cancer
The promise of automated liver disease risk stratification in primary care
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations
Primary care diagnostic pathways for lower gastrointestinal symptoms
Retraction—Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease – Authors’ reply
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis – Authors’ reply
Eligibility for antiviral therapy in Senegal according to 2024 WHO hepatitis B guidelines
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study
Rome Foundation and international neurogastroenterology and motility societies’ consensus on idiopathic gastroparesis
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
